SpartanNash supplements proxy disclosure on merger valuation amid shareholder litigation; meeting set for Sept 9

SpartanNash Co

Two shareholder lawsuits filed in NY alleging incomplete proxy for $SPTN merger with C&S; company denies wrongdoing but voluntarily supplements.
Supplemental disclosure adds BofA's selected companies analysis with EV/EBITDA multiples of 5.2x-7.3x for peers; SPTN standalone multiple 5.0x.
Precedent transaction multiples range from 5.4x to 11.1x; BofA applied reference range of 5.50x-7.25x to SPTN.
Net debt of $761M used in DCF and precedent analyses; special shareholder meeting remains September 9, 2025.
Company states supplemental disclosures will not affect merger consideration or meeting timing.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.